The estimated Net Worth of Michael Gutch is at least $2.23 Million dollars as of 19 October 2021. Michael Gutch owns over 3,759 units of Albireo Pharma Inc stock worth over $2,041,540 and over the last 7 years he sold ALBO stock worth over $11,991. In addition, he makes $179,315 as Independent Director at Albireo Pharma Inc.
Sign up
Michael Gutch ALBO stock SEC Form 4 insiders trading
Michael has made over 1 trades of the Albireo Pharma Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,759 units of ALBO stock worth $11,991 on 19 October 2021.
The largest trade he's ever made was selling 3,759 units of Albireo Pharma Inc stock on 19 October 2021 worth over $11,991. On average, Michael trades about 235 units every 0 days since 2017. As of 19 October 2021 he still owns at least 46,241 units of Albireo Pharma Inc stock.
You can see the complete history of Michael Gutch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Gutch biography
Dr. Michael Gutch Ph.D. is an Independent Director of Albireo Pharma Inc. He served on Albireo Limited's board of directors from October 2015 to November 2016. Since April 2017, Dr. Gutch has served as the Chief Business Officer and Chief Financial Officer of Entasis Therapeutics, a biotechnology company. From January 2014 to March 2017, he served as Executive Director of Corporate Development and Head of Equities at AstraZeneca, a global biopharmaceutical company. Dr. Gutch also served as Managing Director, Medimmune Ventures, the corporate venture capital arm of AstraZeneca from September 2011 to December 2013. Dr. Gutch served as Investment Director, HIG BioVentures of the investment firm HIG Capital from February 2008 to September 2011. Dr. Gutch has previously served as a Director of numerous private biotechnology companies and nonprofit organizations. Dr. Gutch holds an MBA in Finance from Indiana University and a Ph.D. in Molecular Pathology from SUNY Stony Brook. He earned his Bachelor's degrees in Biology and Chemistry from Alfred University.
What is the salary of Michael Gutch?
As the Independent Director of Albireo Pharma Inc, the total compensation of Michael Gutch at Albireo Pharma Inc is $179,315. There are 9 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.
How old is Michael Gutch?
Michael Gutch is 54, he's been the Independent Director of Albireo Pharma Inc since 2016. There are 14 older and 5 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
What's Michael Gutch's mailing address?
Michael's mailing address filed with the SEC is C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON, MA, 02109.
Insiders trading at Albireo Pharma Inc
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs, and Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
What does Albireo Pharma Inc's logo look like?
Complete history of Michael Gutch stock trades at Albireo Pharma Inc and Entasis Therapeutics Inc
Albireo Pharma Inc executives and stock owners
Albireo Pharma Inc executives and other stock owners filed with the SEC include:
-
Ronald Cooper,
President, Chief Executive Officer, Director -
Pamela Stephenson,
Chief Commercial Officer -
Jan Mattsson,
Chief Scientific Officer -
Martha Carter,
Chief Regulatory Officer -
Ronald H. W. Cooper,
CEO, Pres & Director -
Patrick Horn,
Chief Medical Officer -
Martha J. Carter,
Chief Regulatory Officer -
Simon Nicolas Reade Harford,
CFO & Treasurer -
David Chiswell,
Independent Chairman of the Board -
Davey Scoon,
Independent Director -
Michael Gutch,
Independent Director -
Roger Jeffs,
Independent Director -
Stephanie Okey,
Independent Director -
Anne Klibanski,
Independent Director -
Jason Duncan,
Chief Legal Officer, General Counsel, Secretary -
Michelle Graham,
Chief Human Resource Officer -
Simon Harford,
Chief Financial Officer, Treasurer -
Jason G. Duncan,
Chief Legal Officer, Gen. Counsel & Sec. -
Pamela Stephenson M.P.H.,
Chief Commercial Officer -
Dr. Kristina Torfgard,
VP & Global Project Head -
Michelle Graham,
Chief HR Officer -
Joan Connolly,
Chief Technology Officer -
Dr. Jan P. Mattsson Ph.D.,
Chief Scientific Officer, MD (Sweden) & Co-Founder -
Dr. Per-Goran Gillberg,
Co-Founder & VP of Devel. -
Denise Scots Knight,
Director -
Julia R Brown,
Director -
Heather Preston,
Director -
Paresh Soni,
Chief Medical Officer -
Thomas A. Shea,
CFO and Treasurer -
Peter A Zorn,
Senior VP, Corp Dev, GC & Sec -
Plcastrazeneca Ab Astrazeneca,
-
Paul Streck,
Chief Medical Officer -
Advisors Llcperceptive Life...,
-
Partners Ltd Phase4 Venture...,
-
Craig C. Hopkinson,
Director -
Susan Alesina,
Director -
Habib J Dable,
Director